Logo
Apparel & Fashion

Description

Atomoxetine HCI is a premium bulk active pharmaceutical ingredient manufactured to the highest quality standards for ADHD treatment formulations. Produced in an FDA-approved facility located in Maharashtra, this API meets multiple international pharmacopeial specifications including IP, BP, EP, and USP grades, ensuring global regulatory acceptance. The material is available for immediate shipment from ready stock, providing pharmaceutical manufacturers with a reliable supply chain solution for their production schedules. Its consistent purity and stability characteristics make it an ideal choice for developing various dosage forms that require precise active ingredient performance.

Pharmaceutical companies worldwide utilize this Atomoxetine HCI API in manufacturing both generic and branded non-stimulant medications for Attention Deficit Hyperactivity Disorder. The compound is particularly valued for pediatric formulations where stimulant alternatives are preferred, and for adult patie...
Atomoxetine HCI is a premium bulk active pharmaceutical ingredient manufactured to the highest quality standards for ADHD treatment formulations. Produced in an FDA-approved facility located in Maharashtra, this API meets multiple international pharmacopeial specifications including IP, BP, EP, and USP grades, ensuring global regulatory acceptance. The material is available for immediate shipment from ready stock, providing pharmaceutical manufacturers with a reliable supply chain solution for their production schedules. Its consistent purity and stability characteristics make it an ideal choice for developing various dosage forms that require precise active ingredient performance.

Pharmaceutical companies worldwide utilize this Atomoxetine HCI API in manufacturing both generic and branded non-stimulant medications for Attention Deficit Hyperactivity Disorder. The compound is particularly valued for pediatric formulations where stimulant alternatives are preferred, and for adult patients requiring long-term symptom management. Industries depend on its batch-to-batch consistency to maintain uniform therapeutic efficacy in final products, supporting healthcare providers with reliable treatment options across diverse patient populations and age groups.

Choosing this Atomoxetine HCI API delivers significant business value through reduced supply chain complexity and assured regulatory compliance. The ready stock availability minimizes production delays, while the multiple pharmacopeial certifications streamline validation processes for manufacturers. The product's inherent stability contributes to extended shelf life of finished medications, enhancing inventory management efficiency. This reliability enables businesses to maintain consistent product quality, build trust with healthcare providers, and meet growing global demand for effective ADHD treatments.

Key Features:
- Manufactured in an FDA-approved facility ensuring regulatory compliance
- Available in IP, BP, EP, USP, and injectable pharmaceutical grades
- Ready stock maintained for immediate shipment and supply chain reliability
- Meets multiple international pharmacopeial standards for global acceptance
- High-purity bulk API with consistent batch-to-batch quality

Benefits:
- Reduces validation time and costs with comprehensive regulatory documentation
- Minimizes production delays through ready stock availability
- Ensures global market access with multiple pharmacopeial compliances
- Provides reliable therapeutic performance in final dosage forms
- Supports efficient inventory management with stable shelf characteristics

Specifications

Additional Information
Country of OriginIndia

Application

Atomoxetine HCI API serves as the critical active ingredient in non-stimulant medications for Attention Deficit Hyperactivity Disorder. Pharmaceutical manufacturers rely on this bulk raw material to formulate capsules, tablets, and specialized pediatric dosages that meet strict international pharmacopeial standards, ensuring consistent therapeutic outcomes for patients requiring alternative treatment options. This high-purity API enables the development of both immediate-release and extended-release formulations, improving patient compliance through tailored dosing regimens. Its stability and compatibility with various excipients make it suitable for producing medications approved for children, adolescents, and adults, supporting global healthcare systems with reliable ADHD treatment solutions. - Manufacturing FDA-approved non-stimulant medications for pediatric and adult ADHD patients - Producing extended-release capsules that improve daily dosing compliance - Formulating combination therapies for patients with comorbid conditions - Supplying generic pharmaceutical companies with quality bulk API for affordable medications - Enabling the production of stable, shelf-ready finished dosage forms for global distribution

Trade Details

Available StockIn Stock
Sample AvailabilityNo

Payment Terms

Payment Terms
  • Custom Terms (manual entry)

Company Profile

A. S. Joshi & Company, Maharashtra
TruBasic
IndiaMaharashtra, India
Distributor / Wholesaler•Importer / Exporter
Factory Details
Factory SizeBelow 1000 sqm
Annual Production Capacity0

Bulk Atomoxetine HCI API ADHD Treatment Raw Material FDA Approved

Premium Atomoxetine HCI API bulk raw material for ADHD treatment, manufactured in an FDA-approved facility. Available in IP, BP, EP, USP, and injectable grades for reliable pharmaceutical production.

Min. Order Quantity: 1 unit

Shipping

Shipping fee and delivery date to be negotiated. Contact supplier now for more details.

A. S. Joshi & Company
TruBasic
IndiaMaharashtra, India
Distributor / Wholesaler

More Products From Supplier